{
  "id": 18981801,
  "title": "Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?",
  "url": "https://urgent.news/2026/11/08/revolution-medicines-pancreatic-cancer-drug-nearly-doubled-survival-18981801",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-08T16:35:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/revolution-medicines-pancreatic-cancer-drug-nearly-doubled-survival-high-flying-stock"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsIts lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?",
        "url": "https://urgent.news/2026/11/08/revolution-medicines-pancreatic-cancer-drug-nearly-doubled-survival",
        "published": "2026-11-08T16:15:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}